
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1002 | 914 | 945 | 1203 | 1387 | 1478 |
Fund Return | 0.19% | -8.58% | -5.55% | 6.35% | 6.77% | 3.98% |
Place in category | 160 | 170 | 147 | 43 | 106 | 100 |
% in Category | 85 | 93 | 80 | 18 | 61 | 79 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity 500 Index Institutional Pr | 632.47B | 1.44 | 12.54 | 12.97 | ||
Fidelity Contrafund | 144.79B | 3.52 | 17.24 | 15.17 | ||
Fidelity Total Market Index Instl b | 106.34B | 1.12 | 11.54 | 12.30 | ||
Fidelity Blue Chip Growth | 61.8B | -2.84 | 15.11 | 17.11 | ||
Fidelity Growth Company | 57.87B | -3.07 | 14.73 | 17.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Health Care Adm | 34.63B | 4.15 | 4.94 | 7.02 | ||
T. Rowe Price Health Sciences | 7.19B | 4.25 | 3.25 | 8.01 | ||
Fidelity Select Health Care | 6.74B | 2.50 | 3.68 | 7.60 | ||
Vanguard Health Care Inv | 6.25B | 4.15 | 4.89 | 6.97 | ||
T. Rowe Price Health Sciences I | 5.05B | 4.29 | 3.39 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AbbVie | US00287Y1091 | 23.22 | 186.91 | -7.31% | |
Regeneron Pharma | US75886F1075 | 6.90 | 572.91 | -6.18% | |
Amgen | US0311621009 | 6.50 | 294.26 | -5.03% | |
Alnylam | US02043Q1076 | 5.57 | 235.57 | -10.14% | |
Vertex | US92532F1003 | 5.07 | 474.62 | -1.94% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review